| Similar Articles |
|---|
 |
Chemistry World
July 31, 2013
Daniel Johnson |
Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs.   |
Chemistry World
September 30, 2014
Phillip Broadwith |
Lumara splits and sells to AMAG and Perrigo Women's health specialist Lumara is to be split in two and sold to AMAG and consumer healthcare firm Perrigo. |
Chemistry World
October 28, 2015
Phillip Broadwith |
Job cuts at Daiichi, Perrigo and Cabot Three pharma firms -- Daiichi Sankyo, Perrigo and Allergan -- and specialty chemicals company Cabot are to cut thousands of jobs between them in restructuring efforts. |
Chemistry World
September 12, 2011
Andrew Turley |
Ireland Still Attractive to Pharma Industry The drug industry is still keen to invest in Ireland. |
Chemistry World
November 22, 2010
Akshat Rathi |
Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax. |
Chemistry World
May 1, 2015
Rebecca Trager |
Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva. |
Chemistry World
April 13, 2015
Emma Stoye |
Generics giant Mylan offers $30 billion for Perrigo Generics manufacturer Mylan has made an unsolicited, public offer to buy Ireland-based rival Perrigo for $205 per share. |
Chemistry World
December 8, 2015
Phillip Broadwith |
Perrigo nabs US rights to AZ Crohn's drug Irish drug maker Perrigo has fended off a hostile takeover bid from rival Mylan, and agreed to buy the US distribution rights to AstraZeneca's gastroenterology drug Entocort (budesonide). |
The Motley Fool
June 14, 2004
Brian Gorman |
Elan Teams Up With Lilly The companies' manufacturing agreement may be more of a positive sign for Eli Lilly than it is for Elan. |
The Motley Fool
February 27, 2009
Brian Orelli |
Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already. |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma. |
The Motley Fool
August 1, 2008
Brian Lawler |
Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug. |
Chemistry World
August 7, 2012
Anthony King |
Irish pharma exports tumble Irish pharma exports to the US declined 30% in the first six months of this year as a clatter of blockbuster drugs made in Ireland, such as Lipitor (atorvastatin), came off patent. |
The Motley Fool
March 15, 2007
Anders Bylund |
Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades. |
The Motley Fool
February 27, 2009
Mike Pienciak |
A Real Estate Stock With Healthy Potential If you're attracted by the prospect of substantial dividend income, plus modest capital appreciation, you may not have to wait for further market decline to confidently snap up shares of REIT Omega Healthcare. |
The Motley Fool
July 20, 2005
Warren Gump |
Will Perrigo's Prescription Work? Perrigo, the nation's largest maker of private-label over-the-counter (OTC) drugs, is setting new 52-week lows. Nonetheless, if management delivers as it has over the past few years, the longer-term outlook looks promising. |
The Motley Fool
October 25, 2007
Brian Lawler |
Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation? |
Bank Systems & Technology
February 27, 2009
Orla O'Sullivan |
Millions Walk From Irish Bank Amid Shoddy Security Public outcry in Ireland that an estimated 7 million Euro was stolen from the country's biggest bank because of poor procedures. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
BusinessWeek
November 11, 2010
Brown & Dobson |
A Mighty Euro Made in Germany The euro climbs against the dollar as the strength in German exports trumps debt worries about Ireland and Greece. |
AskMen.com
Robert-Jan Broer |
Omega Speedmaster Co-Axial Chronograph We love the Speedmaster. No matter where you are when it comes to watch collecting -- Swatch or Audemars Piguet -- an Omega Speedmaster is always interesting. |
The Motley Fool
May 6, 2008
Brian Orelli |
Free Drugs Free over-the-counter drugs are a win-win for health insurers and their members. |
Pharmaceutical Executive
June 1, 2013 |
Country Report: Ireland Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eye catching. |
CFO
June 1, 2011
Janet Kersnar |
Back on the Map Ireland's domestic economy may be in shambles, but expansion-minded U.S. firms see plenty of opportunity there. |
The Motley Fool
May 26, 2011
Brian Orelli |
Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis. |
The Motley Fool
June 1, 2009
Brian Orelli |
Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what? |
The Motley Fool
November 29, 2010
Dan Caplinger |
This Tax Benefit Is Getting Less Flexible Flexible spending plans are still useful, but beware of some major changes. |
The Motley Fool
June 29, 2009
Brian Orelli |
Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder. |
The Motley Fool
March 31, 2011
Brian Orelli |
Johnson & Johnson Hires a Babysitter J&J tries to turn the OTC business around; the McNeil Consumer Health care unit will now be headed up by Patrick Mutchler, previously the head of the health-care giant's baby products.. |
The Motley Fool
May 31, 2005
David Meier |
Spinoff Alert: Mestek Could Omega Flex be more competitive on its own? It will be interesting to see how it all plays out, especially since there is no analyst coverage for Mestek, a metal forming and HVAC company, and there is only 36% institutional ownership. |
The Motley Fool
February 10, 2009
Brian Orelli |
Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma. |
The Motley Fool
December 15, 2009
Brian Orelli |
Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again. |
